Samsung invests in Cartography Biosciences to advance oncology pipeline

Samsung Life Science Fund announced Thursday a strategic investment in Cartography Biosciences, an American biotech firm specializing in antibody-based oncology therapies. The partnership aims to speed up the development of novel cancer therapies by leveraging Cartography Biosciences’ antigen discovery and drug development capabilities alongside Samsung’s global expertise in life sciences investment and strategic development. “Cartography Biosciences represents a new generation of biotechnology

By The Korea Herald